Leukotriene Receptor Antagonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-analysis
DOI:
https://doi.org/10.2340/actadv.v105.43140Keywords:
Atopic dermatitis, Leukotriene Receptor antagonists, MontelukastAbstract
Atopic dermatitis is a chronic skin condition with no cure. Current conventional treatments can have many side effects or are expensive. Emerging evidence suggests leukotriene receptor antagonists could serve as a corticosteroid-sparing option. This meta-analysis examined 26 studies on the efficacy of leukotriene receptor antagonists for treating atopic dermatitis across 742 participants. There were non-significant reductions in atopic dermatitis severity overall. However, in subgroup analyses montelukast significantly reduced Severity Scoring of Atopic Dermatitis scores in adult populations (SMD = –0.94, 95% CI –1.35 to –0.54, p < 0.0001) and also when compared with conventional treatment rather than placebo (SMD = –0.84, 95% CI –1.21 to –0.47, p < 0.0001). Studies excluded from the statistical analysis generally showed a positive trend favouring montelukast, even if results were not statistically significant. Montelukast shows potential as an adjunct therapy in atopic dermatitis, particularly in adults, but its efficacy is inconsistent. While it may help with pruritus, it should not replace standard treatments. Future research should focus on standardized assessments and personalized approaches to clarify its role in atopic dermatitis management.
Downloads
References
Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387: 1109–1122.
https://doi.org/10.1016/S0140-6736(15)00149-X
Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242: 233–246.
https://doi.org/10.1111/j.1600-065X.2011.01027.x
Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71: 116–132.
https://doi.org/10.1016/j.jaad.2014.03.023
Jo-Watanabe A, Okuno T, Yokomizo T. The role of leukotrienes as potential therapeutic targets in allergic disorders. Int J Mol Sci 2019; 20: 3580.
https://doi.org/10.3390/ijms20143580
Honda T, Kabashima K. Prostanoids and leukotrienes in the pathophysiology of atopic dermatitis and psoriasis. Int Immunol 2019; 31: 589–595.
https://doi.org/10.1093/intimm/dxy087
Pratamasari MA, Hoetomo MM, Hidayati AN. Urinary leukotriene e4 level profile in various degrees of severity in atopic dermatitis patients in dermatovenereology outpatient clinic Dr. Soetomo General Hospital, Surabaya: a descriptive study. Dermatol Reports 2019;11: s1.
Morais-Almeida M, Cabral AJ. Off-label prescribing for allergic diseases in pre-school children. Allergol Immunopathol (Madr) 2014;42: 342–347.
https://doi.org/10.1016/j.aller.2013.02.011
Biswas P, Wilton LV, Shakir SA. Montelukast and improvement of eczema: observations from a prescription event monitoring study in England. Int J Clin Pharmacol Ther 2001; 39: 529–533.
https://doi.org/10.5414/cpp39529
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
https://doi.org/10.1136/bmj.n71
Nettis E, Pannofino A, Fanelli M, Ferrannini A, Tursi A. Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta Derm Venereol 2002; 82: 297–298.
https://doi.org/10.1080/000155502320323298
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ 2011; 343: d5928.
https://doi.org/10.1136/bmj.d5928
Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 2020; 18: 2127–2133.
R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2024. https://www.R-project.org/
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Chapter 10: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from: www.training.cochrane.org/handbook.
Angelova-Fischer I, Tsankov N. Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast. Acta Derm Venereol Alp Panonn Adriat 2005; 14: 115–119.
Broshtilova V, Gantcheva M. Therapeutic Hotline: Cysteinyl leukotriene receptor antagonist montelukast in the treatment of atopic dermatitis. Dermatol Ther 2010; 23: 90–93.
https://doi.org/10.1111/j.1529-8019.2009.01295.x
Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol 2001; 11: 209–213.
Carucci JA, Washenik K, Weinstein A, Shupack J, Cohen DE. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998; 134: 785–786.
https://doi.org/10.1001/archderm.134.7.785
Craig T, Correale C, Chinchilli V, Lehman E, Mende C, Longernecker A, et al. The effects of montelukast on atopic dermatitis (AD): a placebo-controlled, double-blind, parallel study. J Allergy Clin Immunol 2002; 109: 10.
https://doi.org/10.1016/S0091-6749(02)81608-6
Ehlayel MS, Bener A, Sabbah A. Montelukast treatment in children with moderately severe atopic dermatitis. Eur Ann Allergy Clin Immunol 2007; 39: 232–236.
Friedmann PS, Palmer R, Tan E, Ogboli M, Barclay G, Hotchkiss K, et al. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin Exp Allergy 2007; 37: 1536–1540.
https://doi.org/10.1111/j.1365-2222.2007.02811.x
Friedmann PS, Perzanowska M, McGuire C, Nayak N, Clough GF, Sampson AP, et al. New therapeutic indications for Cys-LT1 antagonists: atopic dermatitis and urticaria. Clin Exp Allergy Rev 2001; 1: 156–159.
https://doi.org/10.1046/j.1472-9725.2001.00030.x
Goh A, Lowe A, Zallmann S, Su J. The effectiveness of montelukast as adjunct treatment among children with atopic dermatitis: an open-label, randomized controlled trial. Australas J Dermatol 2016; 57: 52.
Ibrahim HM, Mohamed AH, Atalla RB, Ahmed AM, Hamada HYI. Effectiveness of montelukast in modulation of filaggrin mutation 2282del4 in atopic dermatitis Egyptian patients. J App Pharm Sci 2014; 4: 014–020.
https://doi.org/10.7324/JAPS.2014.40103
Jamalyan KR, Azaryan HG. Comparative efficacy of combined antihistamine and montelukast therapy in adult patients with atopic dermatitis. Postepy Dermatol Alergol 2024; 41: 32–40.
https://doi.org/10.5114/ada.2023.135759
Jeon YH, Min TK, Yang HJ, Pyun BY. A double-blind, randomized, crossover study to compare the effectiveness of montelukast on atopic dermatitis in Korean children. Allergy Asthma Immunol Res 2016; 8: 305–311.
https://doi.org/10.4168/aair.2016.8.4.305
Kägi MK. Leukotriene receptor antagonists: a novel therapeutic approach in atopic dermatitis? Dermatology 2001; 203: 280–283.
https://doi.org/10.1159/000051772
Lee CK, Ku BS, Kim KH, Young KL. The effect of montelukast in the treatment of atopic dermatitis through the SCORAD index. J Am Acad Dermatol 2007; 56: AB68.
https://doi.org/10.1016/j.jaad.2006.10.335
Lehtimäki L, Petäys T, Haahtela T. Montelukast is not effective in controlling allergic symptoms outside the airways: a randomised double-blind placebo-controlled crossover study. Int Arch Allergy Immunol 2009; 149: 150–153.
https://doi.org/10.1159/000189198
Melamed IR. The benefit of montelukast in atopic dermatitis induced by food allergies. J Allergy Clin Immunol 2010; 125: AB93.
https://doi.org/10.1016/j.jaci.2009.12.366
Pei AY, Chan HH, Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr Allergy Immunol 2001; 12: 154–158.
https://doi.org/10.1034/j.1399-3038.2001.012003154.x
Rahman ML, Choudhury AM, Islam MM. Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Med J 2006; 15: 85–88.
https://doi.org/10.3329/mmj.v15i1.8
Sekerel BE, Akpinarli A. The effect of montelukast on allergen-induced cutaneous responses in house dust mite allergic children. Pediatr Allergy Immunol 2003; 14: 212–215.
https://doi.org/10.1034/j.1399-3038.2003.00038.x
Silverberg NB, Paller AS. Leukotriene receptor antagonists are ineffective for severe atopic dermatitis. J Am Acad Dermatol 2004; 50: 485–486.
https://doi.org/10.1016/s0190-9622(03)00758-8
Veien NK, Busch-Sørensen M, Stausbøl-Grøn B. Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2005; 53: 147–149.
https://doi.org/10.1016/j.jaad.2004.12.011
Xabibullayevna MM, Telmanovna AD, Gayratovna AD, Abdukarimovna SM, Masrurovna AM. Antileukotriene drugs in the treatment of atopic dermatitis in children. Int J Pharm Res 2021; 13: 2117.
Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 2001; 44: 89–93.
https://doi.org/10.1067/mjd.2001.111352
Zabawski EJ Jr, Kahn MA, Gregg LJ. Treatment of atopic dermatitis with zafirlukast. Dermatol Online J 1999; 5: 10.
https://doi.org/10.5070/D3589055T9
Chin WK, Lee SWH. A systematic review on the off-label use of montelukast in atopic dermatitis treatment. Int J Clin Pharm 2018; 40: 963–976.
https://doi.org/10.1007/s11096-018-0655-3
Ferguson L, Futamura M, Vakirlis E, Kojima R, Sasaki H, Roberts A, et al. Leukotriene receptor antagonists for eczema. Cochrane Database Syst Rev 2018; 10: CD011224.
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Safa Fawaza Mahmood, Wafa Nawafa Mahmood, Omnia Mohamed Abdalla, Afra Nazar, Hadeeqah Zayaan Riaz, Soha Elmorsy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
